PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Want to see TSE:MDMA full AI Analyst Report?
Top Page
PharmAla Biotech Holdings, Inc.
(MDMA)
Select Model
Select Model
Rating:50Neutral
Price Target:
C$0.16
▲(45.45% Upside)
Action:Reiterated
Date:04/24/26
The score is held back primarily by weak financial performance (negative gross profit, ongoing losses, and continued cash burn), partially offset by a debt-free balance sheet. Technicals are supportive with price above major moving averages and positive MACD, but overbought RSI reduces confidence. Valuation remains pressured due to negative earnings and no dividend support.
Positive Factors
Debt-Free Balance Sheet
A zero-debt capital structure provides durable financial flexibility, lowering near-term default risk and preserving borrowing capacity to fund trials or scale manufacturing. Over 2-6 months this supports survival and optionality while the company seeks to improve cash generation.
Negative Factors
Negative Unit Economics
Negative gross profit signals that product and manufacturing costs exceed revenues, a structural profitability problem. Unless unit economics are improved through cost reductions, pricing, or scale, the business cannot sustainably cover operating expenses, undermining long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A zero-debt capital structure provides durable financial flexibility, lowering near-term default risk and preserving borrowing capacity to fund trials or scale manufacturing. Over 2-6 months this supports survival and optionality while the company seeks to improve cash generation.
Read all positive factors
PharmAla Biotech Holdings, Inc. (MDMA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$15.24M
Dividend YieldN/A
Average Volume (3M)208.17K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue Growth125.00%
EPS Growth25.37%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmAla Biotech Holdings, Inc. Business Overview & Revenue Model
Company Description
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. T...
How the Company Makes Money
null...
PharmAla Biotech Holdings, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 889.57K | 605.50K | 1.04M | 532.00K | 78.07K | 0.00 |
| Gross Profit | -523.49K | -845.17K | 887.44K | 454.10K | 75.78K | -303.00 |
| EBITDA | -1.55M | -2.07M | -573.36K | -710.18K | -973.45K | -2.51M |
| Net Income | -1.63M | -2.18M | -823.60K | -779.81K | -985.58K | -2.51M |
Balance Sheet | ||||||
| Total Assets | 3.13M | 3.42M | 2.90M | 2.41M | 2.33M | 2.79M |
| Cash, Cash Equivalents and Short-Term Investments | 564.71K | 960.66K | 419.38K | 195.04K | 852.14K | 2.47M |
| Total Debt | 0.00 | 0.00 | 0.00 | 253.54K | 0.00 | 0.00 |
| Total Liabilities | 973.42K | 961.73K | 916.88K | 1.03M | 423.78K | 138.48K |
| Stockholders Equity | 2.16M | 2.46M | 1.98M | 1.38M | 1.91M | 2.66M |
Cash Flow | ||||||
| Free Cash Flow | -928.74K | -1.05M | -547.78K | -846.39K | -1.62M | -435.76K |
| Operating Cash Flow | -918.37K | -1.04M | -321.36K | -339.66K | -625.37K | -173.57K |
| Investing Cash Flow | 769.26K | -935.27K | -226.42K | -506.74K | -994.87K | 629.22K |
| Financing Cash Flow | -3.05K | 1.60M | 772.12K | 189.29K | 0.00 | 2.02M |
PharmAla Biotech Holdings, Inc. Technical Analysis
Neutral
0.11
Price Trends
0.14
Positive
0.12
Positive
0.12
Positive
Market Momentum
<0.01
Positive
45.26
Neutral
23.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDMA, the sentiment is Neutral. The current price of 0.11 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.14, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 23.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MDMA.
PharmAla Biotech Holdings, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$15.24M | -9.34 | -78.88% | ― | 125.00% | 25.37% | |
47 Neutral | C$5.82M | 0.79 | 123.88% | ― | ― | 60.66% | |
42 Neutral | C$5.46M | -4.97 | -112.32% | ― | ― | 26.95% | |
40 Underperform | C$8.97M | -5.53 | 21.59% | ― | ― | -36.36% |
* Healthcare Sector Average
TSE:MDMA
PharmAla Biotech Holdings, Inc.
0.14
0.04
33.33%
TSE:CSCI
COSCIENS Biopharma
2.69
-2.37
-46.84%
TSE:APS
Aptose Biosciences
2.28
-0.14
-5.79%
TSE:PREV
PreveCeutical Medical
0.02
-0.02
-57.14%
TSE:PHRM
PharmaTher Holdings Ltd
0.06
-0.16
-72.73%
PharmAla Biotech Holdings, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cortexa Deepens Lead in Australia’s MDMA Market With New GMP Supply and Expanded Access
Positive
Mar 23, 2026
Cortexa, a 50/50 joint venture between PharmAla Biotech and Vitura Health, has reinforced its leadership in Australia’s emerging psychedelic medicines market by commercializing the country’s first large‑scale GMP batch of MDMA ca...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.